Literature DB >> 23744782

Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method.

Shinichi Nakamura1, Takeshi Nakaura, Masafumi Kidoh, Daisuke Utsunomiya, Yasuro Doi, Kazunori Harada, Shozaburou Uemura, Yasuyuki Yamashita.   

Abstract

PURPOSE: To compare the fixed-time- and the test-injection method with respect to the image quality of hypervascular hepatocellular carcinoma (HCC) and the adequacy of timing of the hepatic arterial phase (HAP) in Gd-EOB-DTPA (EOB) enhanced MRI.
MATERIALS AND METHODS: We studied 63 patients with computed tomography (CT) -proven hypervascular HCC: 30 (group 1) were scanned HAP using the fixed-time delay method (protocol 1); in the other 33 (group 2), we applied the test-injection method (protocol 2). We compared the protocols with respect with tumor-to-liver contrast (TLC), contrast-to-noise-ratio (CNR), and relative enhancement of the liver and tumor (REL , RET ) during HAP. Two radiologists compared the adequacy of HAP, image contrast, image noise, and overall image quality.
RESULTS: Under protocol 2, TLC, CNR, and REL and RET of hypervascular HCC were significantly higher (P < 0.01). The proportion of optimal HAP was significantly higher for protocol 2 than protocol 1 (P < 0.01). The visual score of the image contrast and the overall image quality were significantly higher in group 2 than group 1 (P = 0.02 and P = 0.01, respectively).
CONCLUSION: At EOB-enhanced hepatic dynamic MRI, the test-injection method yielded better image quality of hypervascular HCC and improved adequacy of timing of HAP.
Copyright © 2012 Wiley Periodicals, Inc., a Wiley company.

Entities:  

Keywords:  Gd-EOB-DTPA; hepatic arterial phase; hepatic dynamic MRI; hepatocellular carcinoma; test-injection method

Mesh:

Substances:

Year:  2013        PMID: 23744782     DOI: 10.1002/jmri.24017

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

Review 1.  [Modern magnetic resonance imaging of the liver].

Authors:  D M Hedderich; K Weiss; D Maintz; T Persigehl
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

2.  Respiratory Motion-Resolved Compressed Sensing Reconstruction of Free-Breathing Radial Acquisition for Dynamic Liver Magnetic Resonance Imaging.

Authors:  Hersh Chandarana; Li Feng; Justin Ream; Annie Wang; James S Babb; Kai Tobias Block; Daniel K Sodickson; Ricardo Otazo
Journal:  Invest Radiol       Date:  2015-11       Impact factor: 6.016

3.  Spiral flow-generating tube for saline chaser improves aortic enhancement in Gd-EOB-DTPA-enhanced hepatic MRI.

Authors:  Ayumi Iyama; Takeshi Nakaura; Yuji Iyama; Masafumi Kidoh; Yasunori Nagayama; Seitaro Oda; Daisuke Utsunomiya; Tomohiro Namimoto; Kosuke Morita; Koji Yuba; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

4.  Triple Arterial Phase MR Imaging with Gadoxetic Acid Using a Combination of Contrast Enhanced Time Robust Angiography, Keyhole, and Viewsharing Techniques and Two-Dimensional Parallel Imaging in Comparison with Conventional Single Arterial Phase.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Eun Ju Kim; Joon Koo Han
Journal:  Korean J Radiol       Date:  2016-06-27       Impact factor: 3.500

5.  Comparison of the Timing of Hepatic Arterial Phase and Image Quality Using Test-Bolus and Bolus-Tracking Techniques in Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Hepatic Dynamic Magnetic Resonance Imaging.

Authors:  Yuji Iyama; Takeshi Nakaura; Koichi Yokoyama; Masafumi Kidoh; Daisuke Utsunomiya; Seitaro Oda; Tomohiro Namimoto; Yasuyuki Yamashita
Journal:  J Comput Assist Tomogr       Date:  2017 Jul/Aug       Impact factor: 1.826

Review 6.  Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.

Authors: 
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.